Rupert Vessey (Bristol Myers Squibb)

Bris­tol My­ers part­ner comes through on IL-12 ef­fort. Now it's Ru­pert Vessey's turn at bat

Two years ago, Bris­tol My­ers Squibb R&D boss Ru­pert Vessey un­veiled one of the biggest cash deals he’d done, fo­cus­ing on the high-risk, high-re­ward IL-12 tar­get — do­ing it in a deal with re­peat col­lab­o­ra­tor and NK cell en­gager play­er Drag­on­fly Ther­a­peu­tics.

As part of that deal, Vessey hand­ed over $475 mil­lion in near-term cash in ex­change for a glob­al li­cense for Drag­on­fly’s ex­tend­ed half-life cy­tokine DF6002 — a mono­va­lent, IL-12 im­munoglob­u­lin Fc fu­sion pro­tein de­signed to spur a tar­get­ed im­mune re­sponse.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.